Authors


Szilárd Kiss, MD

Latest:

Perspectives on intravenous bevacizumab repackaged for intravitreal use

Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.


Michael W. Stewart, MD

Latest:

Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.


Jordana Joy

Latest:

Inflammasome inhibitor found to reduce GA lesion area growth in clinical study

The lesion area growth was reduced by more than 50% in its first human clinical trial of K8.


Anat Loewenstein, MD, MHA

Latest:

EURETINA leadership welcome record-breaking number of attendees

This year's EURETINA meeting boasts a crowd of 10,000 attendees, including delegates, industry leaders, and young retina specialists.


Eduardo Uchiyama, MD

Latest:

Impressions and take away points from Patient Case #2

A retina specialist discusses impressions and key take away points from patient case.


Ram Yalamanchili

Latest:

Reducing site burden and expanding research capacity with AI

How artificial intelligence could enhance clinical trials.


Marion Munk, MD, PhD

Latest:

Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.




Stela Vujosevic, MD, PhD, FEBO

Latest:

EURETINA 2025: Why the current staging for diabetic eye disease is obsolete

During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.



Jorge Calzada, MD

Latest:

How I use MicroPulse Laser to treat DME

Dr. Jorge Calzada shares his methods for treating diabetic macular edema with MicroPulse Laser and anti-VEGF injections.


Nathan Steinle, MD

Latest:

Key Takeaways on Managing Neovascular AMD and DME

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.


Peter Y. Chang, MD

Latest:

Training and practice are key to learning retinal injection techniques

In-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.


Grazia Pertile, MD

Latest:

Managing retinal folds, role of anterior vitreous in retinal detachments

Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.


Carl D. Regillo, MD, FACS, FASRS

Latest:

Comparing vorolanib intravitreal insert with aflibercept in DME treatment

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.


Esther Lee Kim, MD

Latest:

Transforming preinjection protocols

The role of compounded anesthetic formulations in streamlining efficiency and elevating patient care.


Ronald Frenkel, MD

Latest:

Snowmass Retina & Eye 2025: Ronald Frenkel, MD, previews the unique agenda with a fusion of retina, cataract, and glaucoma

The 15th annual meeting, taking from March 24–28 in Snowmass, Colorado, will deliver high-impact discussions on macular disease, artificial intelligence in ophthalmology, and breakthrough therapies—plus opportunities for networking on and off the slopes.


Priya S. Vakharia, MD

Latest:

Early intervention helps with vision protection in macular degeneration

Retina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.


John Pollack, MD

Latest:

What is encapsulated cell therapy?

John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.




Ali Erginay, MD

Latest:

True-to-life retinal imaging with the new ultra-widefield color RGB modality

Digital exclusive article on red-blue-green ultrawidefield (UWF) imaging


Sydney M Crago

Latest:

Q&A: Amir Kashani on biomarkers for Alzheimer disease

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a noninvasive method for identifying high-risk patients through retinal analysis.


David Almeida, MD, MBA, PhD

Latest:

Two Faricimab Patient Cases from the Real-world in Neovascular AMD

Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.


Lorcan Butler, BSc (Hons), MCOptom, Prof Cert Paed Eye Care

Latest:

A field guide to optic disc drusen

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.


Vasant Raman, MS, FRCS(Glasg)

Latest:

Making the case for nurses to inject dexamethasone implants

Safety data on non-clinician-led services have shown a low complication rate


Leo P. Semes, OD, FAAO

Latest:

The significance of imaging and treatment in lattice retinal degeneration

Prompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.


Ben Shaberman

Latest:

Gene therapy: Where the action is for retinal diseases

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.


Laxmi Devisetty, MD

Latest:

Can AI explain AMD to patients?

Patients weigh in on the value of provider communication.

© 2025 MJH Life Sciences

All rights reserved.